Jump Financial LLC Has $1.01 Million Stake in Trevi Therapeutics, Inc. $TRVI

Key Points

• Jump Financial LLC increased its stake in Trevi Therapeutics by 644.9% in the first quarter, now owning 160,815 shares valued at approximately $1,012,000.
• Trevi Therapeutics reported a quarterly earnings per share of ($0.09), which surpassed analysts' expectations by $0.01, with forecasts predicting an annual EPS of -0.49.
• Several analysts issued positive ratings on Trevi Therapeutics, with price targets ranging from $18.00 to $25.00, and an average target price of $20.11.

Jump Financial LLC raised its position in shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) by 644.9% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 160,815 shares of the company's stock after purchasing an additional 139,226 shares during the quarter. Jump Financial LLC owned 0.16% of Trevi Therapeutics worth $1,012,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. raised its stake in Trevi Therapeutics by 10.0% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 17,925 shares of the company's stock valued at $113,000 after purchasing an additional 1,627 shares during the period. American Century Companies Inc. grew its holdings in shares of Trevi Therapeutics by 2.1% during the 1st quarter. American Century Companies Inc. now owns 79,796 shares of the company's stock valued at $502,000 after acquiring an additional 1,653 shares in the last quarter. Invesco Ltd. grew its holdings in shares of Trevi Therapeutics by 21.2% during the 4th quarter. Invesco Ltd. now owns 23,621 shares of the company's stock valued at $97,000 after acquiring an additional 4,133 shares in the last quarter. Price T Rowe Associates Inc. MD grew its holdings in shares of Trevi Therapeutics by 32.1% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 25,166 shares of the company's stock valued at $104,000 after acquiring an additional 6,119 shares in the last quarter. Finally, Deutsche Bank AG grew its holdings in shares of Trevi Therapeutics by 28.7% during the 1st quarter. Deutsche Bank AG now owns 37,626 shares of the company's stock valued at $237,000 after acquiring an additional 8,383 shares in the last quarter. 95.76% of the stock is owned by institutional investors and hedge funds.

Trevi Therapeutics Trading Up 0.7%

Trevi Therapeutics stock traded up $0.05 on Monday, reaching $7.26. 1,556,560 shares of the stock were exchanged, compared to its average volume of 1,895,919. The stock has a market cap of $884.12 million, a PE ratio of -17.29 and a beta of 0.71. Trevi Therapeutics, Inc. has a twelve month low of $2.36 and a twelve month high of $8.78. The firm has a fifty day moving average price of $6.95 and a two-hundred day moving average price of $6.32.

Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported ($0.09) EPS for the quarter, beating analysts' consensus estimates of ($0.10) by $0.01. Equities analysts anticipate that Trevi Therapeutics, Inc. will post -0.49 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on TRVI shares. D. Boral Capital restated a "buy" rating and set a $21.00 price target on shares of Trevi Therapeutics in a report on Monday, June 2nd. Raymond James Financial lowered their price target on shares of Trevi Therapeutics from $29.00 to $27.00 and set a "strong-buy" rating on the stock in a report on Friday, August 8th. Cantor Fitzgerald started coverage on shares of Trevi Therapeutics in a report on Tuesday, July 1st. They set an "overweight" rating and a $25.00 price target on the stock. Wall Street Zen cut shares of Trevi Therapeutics from a "hold" rating to a "sell" rating in a report on Friday, June 6th. Finally, Oppenheimer restated an "outperform" rating on shares of Trevi Therapeutics in a report on Monday, June 2nd. Two equities research analysts have rated the stock with a Strong Buy rating and eight have assigned a Buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average target price of $20.11.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.